Home › Companies › IMNM

Immunome

IMNM Lead: NDA Submitted 1 Biotech Distilled article ↓

Oncology Protein Radioligand Small Molecule

Most recent annual filing: 2026-03-15

Pipeline (9 active programs)

varegacestat

AL102

Small Molecule Target: gamma secretase, Notch pathway

Desmoid Tumors NDA Submitted oral

IM-1021

Protein Target: ROR1

IM-3050

Radioligand Target: FAP, fibroblast activation protein

Solid Tumors Phase 1

IM-1617

Solid Tumors Phase 1

IM-1340

Solid Tumors Preclinical

IM-1335

Solid Tumors Preclinical

Biotech Distilled coverage (1)

2026-06-22 Immunome, Inc. (IMNM) — Scientific Deep Dive for Varegacestat and the HC74 ADC Pipeline

Articles open on Substack. Some deep dives are subscriber-only.